Treatments

New radiation therapies keep advanced prostate cancer in check

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Treatments for prostate cancer are always evolving, and now research is pointing to new ways of treating a cancer that has just begun to spread, or metastasize, after initial surgery or radiation. Doctors usually give hormonal therapies in these cases to block testosterone, which is a hormone that makes the cancer grow faster. But newer […]

New study compares long-term side effects from different prostate cancer treatments

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Prostate cancer therapies are improving over time. But how do the long-term side effects from the various options available today compare? Results from a newly published study are providing some valuable insights. Investigators at Vanderbilt University and the University of Texas MD Anderson Cancer Center spent five years tracking the sexual, bowel, urinary, and hormonal […]

African American and white men who receive comparable treatments for prostate cancer have similar survival

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Last year, we reported on two studies showing that African American men respond at least as well as white men to prostate cancer treatments given in clinical trials. Nationally, African Americans with prostate cancer are more than twice as likely to die of the disease as their white counterparts, and that has fueled speculation that […]

Most men can hold off on radiation after prostate cancer surgery

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Decisions about follow-up care after prostate cancer surgery sometimes involve a basic choice. If the cancer had features that predict it could return, doctors will likely recommend radiation therapy. But when should a man get that treatment? Should he get the radiation right away, even if there’s no evidence of cancer in the body (this […]

Darolutamide approved for nonmetastatic castration-resistant prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Sometimes after finishing prostate cancer treatment, men get an unwelcome surprise: their prostate-specific antigen (PSA) levels creep higher, suggesting tumors too small to be seen lurk somewhere in the body. This leads to several options. Doctors can continue to monitor a man’s condition with imaging scans. Or, given the anxiety associated with rising PSA, they […]

Common hormonal treatments linked to abnormal heart rhythms and sudden death in men being treated for prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Treatments for advanced prostate cancer that suppress testosterone, a hormone (also called an androgen) that drives the malignant cells to grow and spread, are collectively referred to as androgen deprivation therapies, or ADT. These therapies can significantly extend lifespans in men who have the disease, but they also have a range of challenging side effects. […]

African American men respond better to treatments for advanced prostate cancer in clinical trials

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Racial differences have long been evident in prostate cancer statistics. In particular, African American men are diagnosed with prostate cancer more often than white men, and they’re also nearly twice as likely to die of the disease. But new research also shows that African American men who receive the most advanced treatments for late-stage prostate […]

Cancer treatment: Is a clinical trial right for you?

Some people undergoing cancer treatment may be eligible to participate in a clinical trial of a new drug or therapy. These trials help determine whether a new approach is more effective than standard treatment.

Diet and exercise limit heart disease risk in men undergoing hormonal treatments for advanced prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Men with advanced prostate cancer are typically treated with drugs that prevent the body from making or using testosterone. A hormone (or an androgen, as it’s known), testosterone drives prostate cancer cells to grow faster, so shutting it down is essential to keeping the illness in check. About 600,000 men with advanced prostate cancer in […]

Hormonal therapy for aggressive prostate cancer: How long is enough?

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Men weighing treatment options for intermediate- or high-risk cancer that is still localized to the prostate can face a tricky question. A standard approach in these cases is to give radiation to the prostate along with drugs that block testosterone, a hormone that makes the cancer cells grow faster. For how long should this hormone […]